Navigation Links
Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer

CINCINNATIUniversity of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition.

These findings are being presented via poster at the American Association for Cancer Research International Association for the Study of Lung Cancer Joint Conference on the Molecular Origins of Lung Cancer, Jan. 6-9, 2014, in San Diego.

Non-small-cell lung cancer is any type of lung cancer other than small-cell lung cancerthe most common type of lung cancer. Non-small-cell lung cancer with KRas mutation is non-druggable, and no successful targeted therapy currently exists to help patients with this form of lung cancer.

Nagla Karim, MD, PhD, a member of the institute, assistant professor in the division of hematology oncology at the UC College of Medicine, UC Health physician and principal investigator on this study, says researchers assessed the molecular profiling and sensitivity to the KRas mutant lung cancer in comparison with the wild type, or non-mutant, lung cancer.

"Recent studies suggest that patients with KRas-mutant non-small-cell lung cancer do not often benefit from standard systemic therapies and do not respond to epidermal growth factor receptor inhibitors, which are used to control the progression of cancer," she says.

"There is a need for therapies specifically developed for these patients, and molecular profiling has the potential to identify possible targets that might provide better treatment and innovative targeted therapy for KRas-mutated non-small-cell lung cancer."

The mutation of a KRas gene is an essential step in the development of many cancers, including non-small-cell lung cancer.

In the study, researchers purified RNA from banked tumor and normal lung tissue obtained from 20 patients with wild-type and 17 patients with mutant-type KRas non-small-lung cancer tumors which were being removed in stages I and II.

"We assessed the expression of four genes involved in cell synthesis and repair, and our results show that in mutant-type KRas tumors, the levels of expression of several of three of the genes (BRCA1, TS and SRC) were significantly increased in comparison to normal lung tissue," Karim says. "The expression of the same genes was significantly increased in wild-type KRas tumors relative to their expression in normal lung.

"Interestingly, SRC expression in mutant-type KRas tumors was decreased in comparison to wild-type KRas tumors. These findings suggest that greater expression of the gene ERCC1 in mutant KRas tumors might increase platinum-based chemotherapy resistance in this group of patients, whereas the greater expression of the BRCA1 in wild KRas tumors might suggest sensitivity to taxanes, which are chemotherapy agents."

She adds that this data also suggests that the combination of an approved SRC inhibitor with a TS inhibitor might improve the outcome of patients with wild-type KRas tumors.

"These results shed new light on potentially more effective treatment strategies for patients with various types of KRas-related non-small-cell lung cancer," she says. "We hope that these findings will lead to better therapies and improved outcomes for patients."


Contact: Katie Pence
University of Cincinnati Academic Health Center

Related medicine news :

1. Monoclonal Antibodies Market in Gastric and Esophageal Cancers to Reach USD 766 Mln by 2019, Says GBI Research in Its Report Available at
2. Water Treatment Chemicals Procurement Research Report Now Available from IBISWorld
3. Hair Loss Treatment and Removal in the US Industry Market Research Report from IBISWorld Has Been Updated
4. Researchers report technique that enables patient with word blindness to read again
5. Research into fruit fly cells could lead to cancer insights
6. Virginia Tech researchers find novice teen drivers easily fall into distraction, accidents
7. US global share of research spending declines
8. Anesthetic Drugs Procurement Research Report Now Available from IBISWorld
9. Herpes Cure Research
10. One Minute Herpes Cure Review Can Help People Get Rid Of Their Herpes Quickly And Naturally -
11. Hyper Gain Black: Review Exposes New Supplement Created by A.S. Research
Post Your Comments:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology: